Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Background: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary fibrosis (IPF), but treatment use remains at ∼60%. Objective: To investigate the views of individuals with IPF and pulmonologists on the diagnosis and management of IPF to understand treatment patterns. Methods: Interviews and/or online surveys were completed by patients and pulmonologists from Canada, France, Germany, Italy, Spain, and the UK. Responses from physicians were analyzed by time between diagnosis and treatment initiation in the majority of patients with IPF (group A, > 4 months; group B, ≤4 months). Statistical comparisons between physicians were undertaken using z tests, with p < 0.05 considered statistically significant. Results: The physicians in group A saw fewer patients, were less comfortable discussing the IPF prognosis with patients, and had less belief in the benefits of antifibrotic treatments than the physicians in group B. These physicians’ attitudes contrasted with those of the patients, who wanted more information about the IPF prognosis and pharmacological treatment options at diagnosis and were more concerned about preventing disease progression than avoiding medication side effects. Differences between countries were found regarding physicians’ comfort in discussing the prognosis at diagnosis and access to care. Conclusions: Several barriers to antifibrotic treatment, principally reflecting the differing views and values of patients and physicians, were identified in this study, suggesting a need for better patient-physician communication about pharmacological therapy for IPF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Collard, H. R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70101-8 · Cited by 716
The rising incidence of idiopathic pulmonary fibrosis in the UK
Navaratnam, V., Fleming, K. M., West, J., Smith, C. J. P., Jenkins, R. G., Fogarty, A., & Hubbard, R. B. (2011) · Thorax · doi:10.1136/thx.2010.148031 · Cited by 484
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
Vancheri, C., Failla, M., Crimi, N., & Raghu, G. (2010) · European Respiratory Journal · doi:10.1183/09031936.00077309 · Cited by 464
Nathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Glasscock, K. F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207011 · Cited by 180
Self-citationAlbera, C., Costabel, U., Fagan, E. A., Glassberg, M. K., Gorina, E., Lancaster, L., Lederer, D. J., Nathan, S. D., Spirig, D., & Swigris, J. J. (2016) · European Respiratory Journal · doi:10.1183/13993003.01966-2015 · Cited by 166
Self-citationCommunication and patient participation influencing patient recall of treatment discussions
Richard, C., Glaser, E., & Lussier, M. (2017) · Health Expectations · doi:10.1111/hex.12515 · Cited by 154
European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
Bonella, F., Wijsenbeek, M., Molina-Molina, M., Duck, A., Mele, R., Geissler, K., & Wuyts, W. (2016) · European Respiratory Journal · doi:10.1183/13993003.01204-2015 · Cited by 144
Self-citationCostabel, U., Bendstrup, E., Cottin, V., Dewint, P., Egan, J. J. J., Ferguson, J., Groves, R., Hellström, P. M., Kreuter, M., Maher, T. M., et al. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0112-1 · Cited by 138
Self-citation
Cited by
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Maher, T. M., & Strek, M. E. (2019) · Respiratory Research · doi:10.1186/s12931-019-1161-4 · Cited by 265
“IPF, access/reimbursement issues, and concerns over the adverse effects of antifibrotic drugs [47, 48] (Fig.”
BackgroundSelf-citationBehr, J., Prasse, A., Wirtz, H., Koschel, D., Pittrow, D., Held, M., Klotsche, J., Andreas, S., Claussen, M., Grohé, C., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02279-2019 · Cited by 198
Self-citationMaher, T. M., Kreuter, M., Lederer, D. J., Brown, K. K., Wuyts, W. A., Verbruggen, N., Stutvoet, S., Fieuw, A. M., Ford, P., Abi‐Saab, W., et al. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000422 · Cited by 103
Self-citationEfficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Richeldi, L., Kolb, M., Jouneau, S., Wuyts, W. A., Schinzel, B., Stowasser, S., Quaresma, M., & Raghu, G. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-1030-4 · Cited by 96
Lee, J. Y. T., Tikellis, G., Corte, T. J., Goh, N. S. L., Keir, G. J., Spencer, L. M., Sandford, D., Khor, Y. H., Glaspole, I., Price, J., et al. (2020) · European Respiratory Review · doi:10.1183/16000617.0125-2019 · Cited by 91
Antoniou, K. M., Markopoulou, K., Tzouvelekis, A., Trachalaki, A., Vasarmidi, E., Organtzis, J., Tzilas, V., Bouros, E., Kounti, G., Rampiadou, C., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00172-2019 · Cited by 68
on behalf of the SEPAR-IPF National Registry, Fernández‐Fabrellas, E., Molina‐Molina, M., Soriano, J. B., Portal, J. A. R., Ancochea, J., Valenzuela, C., & Xaubet, A. (2019) · Respiratory Research · doi:10.1186/s12931-019-1084-0 · Cited by 61
“Another survey has recently shown that pulmonologists who initiated the anti-fibrotic treatment after more than 4months of patient’s diagnosis (46% of total) saw fewer patients and had less confidence in the treatment than those who initiated it in ≤4 months [36].”
BackgroundMackintosh, J. A., Keir, G. J., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., WILSHER, M. L., et al. (2024) · Respirology · doi:10.1111/resp.14656 · Cited by 60
“256 As the disease progresses, the loss of independence, greater reliance on others and loss of previous life roles, can elicit strong emotional distress.”
BackgroundAntifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
Salisbury, M. L., Conoscenti, C., Culver, D. A., Yow, E. S., Neely, M. L., Bender, S. D., Hartmann, N., Palmer, S. M., & Leonard, T. B. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201912-880oc · Cited by 56
Evaluation and management of Idiopathic Pulmonary Fibrosis
Kishaba, T. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.02.003 · Cited by 55
Holtze, C. H., Freiheit, E., Limb, S. L., Stauffer, J. L., Raimundo, K., Pan, W. T., Flaherty, K. R., & Kim, H. J. (2020) · Respiratory Research · doi:10.1186/s12931-020-1315-4 · Cited by 52
“Additionally, surveys have been used to explore patient and provider views about IPF treatment in Canada, France, Germany, Italy, Spain and the United Kingdom [10].”
MethodLANCASTER, L. H., Bonella, F., Inoue, Y., Cottin, V., Siddall, J., Small, M., & Langley, J. (2021) · Respirology · doi:10.1111/resp.14154 · Cited by 50
“Pulmonologists who saw fewer patients with IPF were less comfortable discussing a patient’s prognosis, believed less in the effectiveness of antifibrotic therapy, tended to adopt a ‘watch and wait approach’ and were more likely to wait >4 months between diagnosis and treatment initiation.(30) Despite relatively high r…”
BackgroundGale, R. P., Finger, R. P., Eldem, B. M., Aslam, T. M., Barratt, J., Daïen, V., Kodjikian, L., Loewenstein, A., Okada, M., Wong, T. Y., et al. (2022) · Acta Ophthalmologica · doi:10.1111/aos.15201 · Cited by 39
Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end
Wijsenbeek, M. S., Kool, M., & Cottin, V. (2018) · European Respiratory Journal · doi:10.1183/13993003.02111-2018 · Cited by 35
Self-citationMoor, C. C., Mostard, R. L. M., Grutters, J. C., Bresser, P., Aerts, J. G. J. V., Dirksen, C. D., Kimman, M., & Wijsenbeek, M. S. (2020) · Respiratory Research · doi:10.1186/s12931-020-01458-1 · Cited by 33
“In contrast, almost a quarter of the surveyed healthcare providers in that study considered side-effects more important than the risk of disease progression [9].”
BackgroundSelf-citationNathan, S. D., Wanger, J. S., Zibrak, J. D., Wencel, M. L., Burg, C., & Stauffer, J. L. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1816831 · Cited by 38
Self-citationMan, R. K., Gogikar, A., Nanda, A., Janga, L. S. N., Sambe, H. G., Yasir, M., & Ramphall, S. (2024) · Cureus · doi:10.7759/cureus.54268 · Cited by 30
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
Valenzuela, C., Torrisi, S. E., Kahn, N. C., Quaresma, M., Stowasser, S., & Kreuter, M. (2020) · Respiratory Research · doi:10.1186/s12931-019-1269-6 · Cited by 32
Self-citationA scoping review of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis (IPF)
Bramhill, C., Langan, D., Mulryan, H., Eustace‐Cook, J., Russell, A., & Brady, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297832 · Cited by 30
“Treatment pharmaceutical 25 (7) (62) (63) (58) (41) (17) (4) 43) (34) (35) (16) (27) (30) (48) (18) (37) (49) (64) (14) (18) (39) (40) (38) .”
Brereton, C. J., Wallis, T., Casey, M., Fox, L., Pontoppidan, K., Laws, D., Graves, J. E., Titmuss, V., Kearney, S., Evans, S., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00120-2020 · Cited by 29
Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients
Fournier, D., Jouneau, S., Bouzillé, G., Polard, É., Osmont, M., & Scailteux, L. (2022) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2022.102149 · Cited by 33
Maher, T. M., LANCASTER, L. H., Jouneau, S., Morrison, L. D., Lederer, D. J., Molina‐Molina, M., Bendstrup, E. M., Kirchgaessler, K.-U., Gilberg, F., Axmann, J., et al. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201810-720rl · Cited by 29
Self-citationTreatment of idiopathic pulmonary fibrosis with Nintedanib: an update
Wongkarnjana, A., Yanagihara, T., & Kolb, M. R. J. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1673733 · Cited by 25
Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
Patel, H., Shah, J. R., Patel, D., Avanthika, C., Jhaveri, S., & Gor, K. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101484 · Cited by 25
Lee, S. Y., Park, S., Lee, S., Kim, H., Kwon, J.-H., Yoo, J., Kim, K., Park, M. S., Lee, C. G., Elias, J. A., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01066-1 · Cited by 26
Management of Idiopathic Pulmonary Fibrosis
Salisbury, M. L., & Wijsenbeek, M. S. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.004 · Cited by 20
Self-citationDisparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis
Kaul, B., Lee, J. S., Petersen, L. A., McCulloch, C. E., Rosas, I. O., Bandi, V., Zhang, N., DeDent, A. M., Collard, H. R., & Whooley, M. A. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.02.027 · Cited by 18
Komatsu, M., Yamamoto, H., Ichiyama, T., Kawakami, S., Uehara, T., Yoshikawa, Y., Kitaguchi, Y., Ushiki, A., Yasuo, M., & Hanaoka, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262795 · Cited by 18
Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis
Keith, R. C., & Nambiar, A. M. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241309795 · Cited by 20
“51 However, many patients with IPF remain untreated 52–54 or discontinue antifibrotic therapy due to adverse events, most frequently diarrhea.”
Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
Wijsenbeek, M. S., Bonella, F., Orsatti, L., Russell, A., Valenzuela, C., Wuyts, W. A., & Baile, W. F. (2021) · ERJ Open Research · doi:10.1183/23120541.00422-2021 · Cited by 14
Self-citationWu, X., Xiao, X., Chen, X., Yang, M., Hu, Z., Shuai, S., Fu, Q., Yang, H., & Du, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.948101 · Cited by 16
Senhaji, L., Senhaji, N., Abbassi, M., Karhate, M., Serraj, M., Biaze, M. E., Benjelloun, M. C., Ouldim, K., Bouguenouch, L., & Amara, B. (2026) · Biomedicines · doi:10.3390/biomedicines14010090 · Cited by 14
“Regarding the optimal timing to initiate treatment, studies have shown that only 60% of patients diagnosed with IPF in Europe and the United States receive antifibrotic treatment [109,110].”
Wang, J., Fang, Y., Zhou, Y., Chen, Q., Li, J., Du, Y., Cui, X., Qu, Y., & Ge, F. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105881 · Cited by 9
Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis
Xu, H., Hui, S. L., Lee, J. S., Zhang, Z., & Boente, R. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1054oc · Cited by 10
Singer, D., Bengtson, L. G. S., Conoscenti, C., Anderson, A. J., Brekke, L. N., Shetty, S. S., & de Andrade, J. A. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2054203 · Cited by 8
Cottin, V., Bergot, E., BOURDIN, A. A., Nunès, H., Prévôt, G., Wallaert, B., & Marchand-Adam, S. (2021) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2020.100811 · Cited by 9
Xu, W., Li, Q., Mao, Y., & He, Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1397659 · Cited by 7
The unmet care needs of progressive fibrosing interstitial lung disease
Sweeney, D. J., Khor, Y. H., & Goh, N. S. L. (2020) · Respirology · doi:10.1111/resp.13942 · Cited by 7
Development of a Novel Biomarker for the Progression of Idiopathic Pulmonary Fibrosis
Yeo, H. J., Ha, M., Shin, D. H., Lee, H. R., Kim, Y. H., & Cho, W. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010599 · Cited by 9
Antifibrotic in interstitial lung diseases: When, where, and how long?
Rai, D. K., & Tripathi, S. (2022) · Lung India · doi:10.4103/lungindia.lungindia_283_22 · Cited by 5
Rodríguez‐Nieto, M. J., Cano-Jiménez, E., Ortíz, A. D. R., Villar, A., Morros, M., Ramón, A., & Armengol, S. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01278-3 · Cited by 6
Cano-Jiménez, E., Ortíz, A. D. R., Villar, A., Rodríguez‐Nieto, M. J., Ramón, A., & Armengol, S. (2022) · Respiratory Research · doi:10.1186/s12931-022-02154-y · Cited by 5
Sato, R., Handa, T., Tanizawa, K., & Hirai, T. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02795-9 · Cited by 5
“In contrast, several studies have reported that physicians believe they provide sufficient information to patients and caregivers [6, 9, 10].”
BackgroundResultLaCamera, P. P., Limb, S. L., Haselkorn, T., Morgenthien, E. A., Stauffer, J. L., & Wencel, M. L. (2019) · Chronic Respiratory Disease · doi:10.1177/1479973119879678 · Cited by 4
“In comparison, real-world data from a survey of physicians from Canada and Europe showed that most physicians initiated antifibrotic therapy >4 months after diagnosis.(24) It should be noted that regional access to antifibrotic therapies varies and may impact prescribing patterns.”
ResultInfluentialBramhill, C., Langan, D., Mulryan, H., Eustace‐Cook, J., Russell, A., & Brady, A. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-070513 · Cited by 3
Historical eye on IPF: a cohort study redefining the mortality scenario
Tomassetti, S., Ravaglia, C., Piciucchi, S., Ryu, J. H., Wells, A. U., Donati, L., Dubini, A., Klersy, C., Luzzi, V., Gori, L., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1151922 · Cited by 4
“The concern for adverse events and a quote of skepticism on antifibrotic efficacy are still rooted in some pulmonary physicians, leading to the possible risk of delayed treatment (21).”
BackgroundVillar, A., Rodríguez‐Nieto, M. J., Cano-Jiménez, E., Ortiz, A. R., Morros, M., Ramon, A., & Armengol, S. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03186-4 · Cited by 3
“In the present study, lower prescription patterns of antifibrotics were observed, maybe due to physician concerns on risk/benefit profile of antifibrotic treatment, price issues or restrictions due to public policies, among others [2, 35].”
BackgroundCarlson, L., Kalafatis, D., Pesonen, I., Magnusson, J. M., & Sköld, M. C. (2024) · Chronic Respiratory Disease · doi:10.1177/14799731241299443 · Cited by 3
“21 Previous studies suggest that IPF patients initiating anti fi brotic treatment at the time of IPF diagnosis are younger and have worse lung function compared to non-treated patients.”
Tseng, C.-M., Chen, M.-Y., Kao, C.-Y., & Tao, C.-W. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000719 · Cited by 5
Hollmén, M., Bromilow, T., Smith, A. B., Mealing, S., Lewis, D., Galvin, L., Jones, S., Pacheco, L., Soulard, S., & Froidure, A. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s408857 · Cited by 3
“However, Maher et al found that IPF patients wanted more information about the pharmacological treatment options at diagnosis and were more concerned about preventing disease progression than avoiding medication side effects.(13) Therefore, stakeholders must consider which treatment is most appropriate while maintaini…”
BackgroundMethodInfluentialNathan, S. D. (2020) · CHEST Journal · doi:10.1016/j.chest.2019.12.033 · Cited by 3
Self-citationPalliative Aspekte bei interstitiellen Lungenerkrankungen (ILD)
Westhoff, M., & Delis, S. (2025) · Pneumologie · doi:10.1055/a-2624-3671 · Cited by 2
A Cross-Sectional Survey of Pulmonologists Working at Non-ILD Centers in the United States
Biehl, R., Jeganathan, N., Imperio, M., Becerra, B. J., López, D., & Alismail, A. (2023) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s421089 · Cited by 2
Tratamiento farmacológico en la fibrosis pulmonar idiopática. Drogas modificadoras de enfermedad
FLORENZANO, M., V, & C, F. R. (2019) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482019000400287 · Cited by 3
Sakamoto, N., Hamada, N., Okamoto, M., Tobino, K., Ichiyasu, H., Ishii, H., Ichikado, K., Morimoto, S., Hosogaya, N., & Mukae, H. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047249 · Cited by 3
Górska, K., Maskey‐Warzęchowska, M., Barnaś, M., Białas, A. J., Barczyk, A., Jagielska-Len, H., Jassem, E., Kania, A., Lewandowska, K. B., Majewski, S., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221117982 · Cited by 2
Abordagem geral da Fibrose Pulmonar Idiopática
de Souza, R. L., Franco, L. G. M. D. M., & de Siqueira, E. C. (2023) · Revista Eletrônica Acervo Médico · doi:10.25248/reamed.e12623.2023 · Cited by 2
Garrec, M. L., Rousseau, C., Thépault, F., Kerjouan, M., Salé, A., & Jouneau, S. (2021) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2021.100818 · Cited by 2
Tomassetti, S., Sebastiani, A., Caminati, A., Oggionni, T., Davì, M., Ghirardini, A., & Martinoli, M. M. (2021) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v38i3.11400 · Cited by 3
Factors associated with non-intervention of antifibrotic agents in IPF patients
Asami‐Noyama, M., Hamada, K., Asai, Y., Abé, T., Yonezawa, K., Watanabe, M., Hisamoto, Y., Murakawa, K., Fukatsu, A., Matsuda, K. M., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.09.008 · Cited by 2
Current and future treatment for idiopathic pulmonary fibrosis
Choi, W.-I. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.4.256 · Cited by 1
“국제적인 설문 조사에서 호흡기전문의는 25% 정도는 질병의 진행보다 약 물의 부작용을 더 우려하고 있으나, 환자의 경우에는 약물의 부작용보다는 질병의 진행을 예방할 수 있는지에 대한 관심 이 더 많았다[33].”
Beyond standard care?—idiopathic pulmonary fibrosis patients’ perception of care coordinators
Hagmeyer, L., & Randerath, W. J. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.04.40
Idiopathic pulmonary fibrosis management: caring is sparing
Nava, S., & Prediletto, I. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.04.44
Bramhill, C., Langan, D., Mulryan, H., Eustace‐Cook, J., Russell, A., & Brady, A. (2022) · medRxiv · doi:10.1101/2022.11.25.22282749
Generoso, L. N., Assis, M. G., de Leucas, P. L. B., Luz, M. B., Moura, M. P., Silva, M. L. M., & Mancuzo, E. V. (2023) · Research Square · doi:10.21203/rs.3.rs-3038904/v1
Micallef, C. M., Belhassen, M., Fourrier, J.-M., Nolin, M., Bornier, N., Jouneau, S., Kreuter, M., Samara, K. D., & Cottin, V. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2025-003153
Self-citationMoor, C. C., Mostard, R. L. M., Grutters, J. C., Bresser, P., Aerts, J. G. J. V., Dirksen, C. D., Kimman, M. L., & Wijsenbeek, M. S. (2020) · Figshare · doi:10.6084/m9.figshare.12703761
Self-citationCano-Jiménez, E., Romero Ortiz, A. D., Villar, A., Rodríguez-Nieto, M. J., Ramón, A., & Armengol, S. (2022) · Figshare · doi:10.6084/m9.figshare.21062151
Impact of time to diagnosis in patients with progressive fibrotic ILD: a systematic review
Deng, Z., Karrasch, S., Alter, P., Rivera‐Ortega, P., Behr, J., & Jörres, R. A. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2026-004356
Metadata
- Authors
- Maher, T. M., Swigris, J. J., Kreuter, M., Wijsenbeek, M., Cassidy, N., Ireland, L., Axmann, J., & Nathan, S. D.
- Affiliations
- Royal Brompton Hospital (GB)
- National Jewish Health (US)
- Heidelberg University (DE)
- Erasmus MC (NL)
- F. Hoffmann-La Roche AG (CH)
- Inova Fairfax Hospital (US)
- ORCID
- Venue
- Respiration
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 96
- Issue
- 6
- Pages
- 514-524
- ISSN
- 0025-7931 (ISSN-L)
- 1423-0356
- OpenAlex
- W2885464317
- Semantic Scholar
- 601dc0fbcc99d3a67390da0fe6c7502ad83884d7
- Cited by
- 69
- References
- 22
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 9 · 2023: 11 · 2022: 12 · 2021: 8 · 2020: 15 · 2019: 8 · 2018: 1
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Respiration (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- GlaxoSmithKline
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative Care and End-of-Life Issues
- Keywords
- idiopathic pulmonary fibrosis, antifibrotic therapy, barriers to treatment, patient-physician communication, physician attitudes, prognosis disclosure, treatment initiation timing, patient expectations, health care access, disease progression prevention, adverse drug reactions
- MeSH terms
- Pulmonologists, Adult, Anti-Inflammatory Agents, Non-Steroidal, Female, Humans, Indoles, Male, Middle Aged, Pyridones, Surveys and Questionnaires, Idiopathic Pulmonary Fibrosis, Watchful Waiting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.